QUTE-CE MRI for Quantitative Blood-Brain Barrier Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to provide a reliable, quantitative measure of blood-brain barrier (BBB) disruption, particularly in mild traumatic brain injury (mTBI) and vascular dementia, due to inaccuracies in existing MRI techniques like DCE-MRI, which are 15-30% inaccurate and dependent on microstructural properties.
Innovation Solution
The use of quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) with ferumoxytol, a superparamagnetic iron oxide nanoparticle, to determine BBB disruption by measuring signal intensity changes in brain parenchyma or cerebral spinal fluid, allowing for accurate quantification and localization of BBB permeability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DCE-MRI is used to measure BBB permeability, then BBB disruption can be detected, but measurement accuracy deteriorates due to 15-30% inaccuracy in concentration versus time curve
Solution Approach 1:
The patent changes the imaging parameters by using ultra-short time-to-echo (UTE) sequences with TE < 300 μs instead of conventional DCE-MRI parameters. This parameter change allows accurate measurement of contrast agent concentration without the 15-30% inaccuracy that plagues conventional methods, while maintaining BBB disruption detection capability.
Solution Approach 2:
The patent replaces the conventional DCE-MRI measurement system with a QUTE-CE MRI system that uses ultra-short echo time imaging. This substitution eliminates the dependency on accurate concentration versus time curve fitting by directly measuring contrast agent presence and distribution, thereby resolving the measurement accuracy issue.
2Reliability
If DCE-MRI is used to assess BBB permeability, then BBB disruption can be visualized, but measurement reliability deteriorates due to strong dependence on microstructural properties such as vessel size, tortuosity and orientation
Solution Approach 1:
The patent extracts the measurement of BBB disruption from the complex interdependence with microstructural properties by using QUTE-CE MRI to directly measure contrast agent concentration and distribution. This extraction allows BBB permeability assessment independent of vessel size, tortuosity, and orientation, resolving the reliability issue.
Solution Approach 2:
The patent introduces contrast agent concentration as an intermediary measure that directly reflects BBB disruption without being confounded by microstructural properties. By measuring the contrast agent's presence and distribution using QUTE-CE MRI, the system provides a reliable BBB permeability assessment that is not dependent on vessel characteristics.
3Ease of operation
If standard MRI techniques are used to measure BBB disruption, then imaging can be performed, but quantitative measurement capability is lost due to inability to produce reproducible biomarkers
Solution Approach 1:
The patent replaces standard qualitative MRI techniques with quantitative QUTE-CE MRI that provides measurable, reproducible biomarkers. The ultra-short echo time imaging enables objective quantification of contrast agent concentration and BBB disruption, transforming subjective imaging into reliable quantitative measurement with reproducible results.
Solution Approach 2:
The patent changes the imaging approach from standard qualitative MRI to quantitative QUTE-CE MRI with specific parameter settings (TE < 300 μs, TR < 10 ms). These parameter changes enable the system to produce reproducible quantitative biomarkers while maintaining ease of operation through automated measurement and analysis.
4Loss of time
If DCE-MRI is used to model contrast agent effects, then BBB permeability can be assessed, but acquisition time must be shortened which compromises measurement accuracy
Solution Approach 1:
The patent maintains continuous and accurate measurement of contrast agent concentration throughout the acquisition process using QUTE-CE MRI. The ultra-short echo time sequence allows continuous sampling without requiring long acquisition times, thereby maintaining measurement precision while reducing overall acquisition time loss.
Solution Approach 2:
The patent substitutes the conventional DCE-MRI acquisition system with QUTE-CE MRI that uses ultra-short echo time imaging. This substitution enables accurate contrast agent concentration measurement even with shortened acquisition times, resolving the trade-off between time loss and measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
QUTE-CE MRI provides a non-biased, global quantitative assessment of BBB integrity, enabling effective treatment of brain trauma and early diagnosis of vascular dementia by detecting BBB disruption through increased signal intensity and cerebral blood volume changes.
Implementation Method 1
ferumoxytol, a superparamagnetic iron oxide nanoparticle
Implementation Method 2
quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI)
Data Source
AI summary
Disclosed are methods for determining blood brain barrier disruption in a subject in need thereof. The methods include administering intravascularly a contrast agent to the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in brain parenchyma and/or cerebral spinal fluid within the region of interest.